SCHEMBL475120

SCHEMBL475120

O=C(O)c1cc(C(F)(F)F)ccc1Br

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 4/20 0.59
ALDH1A1 P00352 3/20 0.58
HPGD P15428 3/20 0.58
KDM4E B2RXH2 2/20 0.58
HSD17B10 Q99714 2/20 0.58
CES2 O00748 2/20 0.52
USP2 O75604 1/20 0.50
CYP2C19 P33261 1/20 0.50
LIPC P11150 1/20 0.48
LIPG Q9Y5X9 1/20 0.48
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CYP1A2 P05177 1/20 0.46
ALOX12 P18054 1/20 0.46
SORT1 Q99523 2/20 0.46
KDM1A O60341 1/20 0.46
MPO P05164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
SRD5A2 P31213 1/20 0.44
PIM1 P11309 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL28849078 0.98 TAS2R14 (0.57) TAS2R14ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL23411213 0.85 TAS2R14 (0.46) TAS2R14ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL422332 0.85 ALDH1A1 (0.62) TAS2R14ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL27989097 0.83 CES2 (0.50) TAS2R14ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL475119 0.83 CES2 (0.50) TAS2R14ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL151287 0.83 CES2 (0.50) TAS2R14ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL31064612 0.83 CES2 (0.50) TAS2R14ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL12932825 0.83 CES2 (0.50) TAS2R14ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL460066 0.82 KDM4E (0.69) ALDH1A1HPGDKDM4EHSD17B10CES2
SCHEMBL21654060 0.81 TDP1 (0.56) TAS2R14ALDH1A1HPGDHSD17B10SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119285635-A Synthesis of 8H-indolo [3,2,1-DE ] phenanthridine-8-ketone compound from carbazole and o-bromobenzoic acid and synthesis method thereof 陕西科技大学 2025-01-10 CN claimed
CN-116396159-A Synthesis method of 2,2' -biphenyl dicarboxylic acid compound 湖南大学 2023-07-07 CN claimed
CN-119707952-B Thiadiazolidinone derivative with PTPN2/PTPN1 inhibitory activity, and preparation method and application thereof CHINA PHARMACEUTICAL UNIVERSITY (CN) 2026-05-26 CN disclosed
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2026-04-21 US disclosed
US-20250368647-A1 NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2025-12-04 US disclosed
US-12441703-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-10-14 US disclosed
US-20250263416-A1 SPPL2a INHIBITORS INCYTE CORPORATION 2025-08-21 US disclosed
EP-4536660-A1 NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS GlaxoSmithKline Intellectual Property Development Ltd (GB) 2025-04-16 EP disclosed
CN-119707952-A Thiadiazolidinone derivative with PTPN2/PTPN1 inhibitory activity, and preparation method and application thereof 中国药科大学 2025-03-28 CN disclosed
CN-119325476-A Nitrogen-containing condensed 2, 3-dihydroquinazolinone compounds as NAV1.8 inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2025-01-17 CN disclosed
CN-119285635-A Synthesis of 8H-indolo [3,2,1-DE ] phenanthridine-8-ketone compound from carbazole and o-bromobenzoic acid and synthesis method thereof 陕西科技大学 2025-01-10 CN disclosed
US-20070213314-A1 Dibenzyl Amine Compounds and Derivatives PFIZER INC 2007-09-13 US disclosed
US-20070213314-A1 Dibenzyl Amine Compounds and Derivatives PFIZER INC 2007-09-13 US disclosed
US-20070213314-A1 Dibenzyl Amine Compounds and Derivatives PFIZER INC 2007-09-13 US disclosed
US-20070213371-A1 Dibenzyl Amine Compounds and Derivatives PFIZER INC 2007-09-13 US disclosed
EP-1817297-A1 DIBENZYL AMINE COMPOUNDS AND DERIVATIVES Pfizer Products Inc. (US) 2007-08-15 EP disclosed
US-20070082907-A1 Peroxisome proliferator activated receptor modulators ELI LILLY AND COMPANY (IN) 2007-04-12 US disclosed
EP-1697304-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2006-09-06 EP disclosed
WO-2006056854-A1 DIBENZYL AMINE COMPOUNDS AND DERIVATIVES PFIZER PRODUCTS INC. (US) 2006-06-01 WO disclosed
WO-2005054176-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213314-A1 Dibenzyl Amine Compounds and Derivatives APOB, LDLR, CETP TAS2R14 2832/4885ALDH1A1 1853/4885HPGD 1222/4885
US-20250368647-A1 NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN2A, SCN5A TAS2R14 981/4885ALDH1A1 2933/4885HPGD 549/4885
US-12441703-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A TAS2R14 297/4885ALDH1A1 2665/4885HPGD 1512/4885
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives NR3C2, NR5A1, SRD5A2 TAS2R14 793/4885ALDH1A1 1507/4885HPGD 2085/4885
US-20070213371-A1 Dibenzyl Amine Compounds and Derivatives APOB, LDLR, CETP TAS2R14 2832/4885ALDH1A1 1853/4885HPGD 1222/4885
US-20070082907-A1 Peroxisome proliferator activated receptor modulators PPARG, PPARA, PPARD TAS2R14 2854/4885ALDH1A1 1398/4885HPGD 269/4885
US-20250263416-A1 SPPL2a INHIBITORS SPPL2A, SPPL2B, BACE1 TAS2R14 4185/4885ALDH1A1 3087/4885HPGD 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.